About
- About Avecho
- Board & Leadership
TPM^® Technology
Portfolio
Invest
- Investor Centre
- Media Centre
Contact

Hit enter to search or ESC to close

Phosphagenics Appoints Dr Ross Murdoch as Chief Executive Officer

January 14, 2015

Click here to read more

Post navigation

Ethics Approval to Commence Topical TPM®/Oxycodone Patch Trial

Phosphagenics Decides to put its BioElixia Cosmetics Brand up for Sale

Related Posts

Phosphagenics Receives Further Arbitration Process Update

October 23, 2018

Placement to Advance Phase III Clinical Trial

August 28, 2023August 28, 2023

Phosphagenics Announces Results of TPM Oxycodone Phase 2a Trial

January 29, 2016

Recent Posts

Recruitent recommences for phase III insomnia trial
August 31, 2026
Euroz Hartleys | Successful Phase 3 Interim Results
July 8, 2026
Avecho Phase III insomnia trial advances following positive interim analysis
June 24, 2026

Categories

Analyst Coverage
Company Announcement
Company Report
Investor Webinar
Media Coverage
Newsletter
Press Release
Uncategorised

About us

We see a future where more patients can get even more from their treatments through innovative delivery technologies.

Stay Posted

Stay informed about our latest news and developments.

Leave this field empty if you're human:

About Avecho

TPM^® Technology

Portfolio

Investor Centre
- Investor Centre
- Media Centre

© Copyright 2019 Avecho Biotechnology Ltd.